Compare IDEXX Laboratories, Inc. (IDXX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Wayfair Inc — how do they compare? IDEXX Laboratories, Inc. trades at $563.81 (market cap $44.48B), while Wayfair Inc trades at $84.81 (market cap $11.58B). The key difference: IDEXX Laboratories, Inc. is far larger — about 3.8× Wayfair Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | W | |
|---|---|---|
Market Cap | $44.48B | $11.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $119.05 |
52-Week Low | $520.87 | $56.42 |
Enterprise Value | $45.38B | $14.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
Wayfair (W) trades at $87.76, down 1.74% today, showing mixed technical signals with a neutral overall rating. The company continues to face profitability challenges with negative net income margins (-2.41%) despite strong revenue growth to $12.46 billion in 2025. Recent earnings performance has been inconsistent, with a Q2 2026 miss after previous beats. Analyst sentiment remains positive with 52% buy ratings and a $93.58 consensus target, while the company expands into physical retail and leverages AI capabilities.
The stock presents a growth story with improving operational cash flow and market share gains in e-commerce, but faces significant execution risks from high debt levels (95% debt-to-asset ratio) and persistent unprofitability. Current valuation at 0.89 P/S appears reasonable for the sector, though the elevated EV/EBITDA of 110.6 signals premium pricing expectations. Near-term catalysts include the July Black Friday sale and brick-and-mortar expansion, but macroeconomic pressures on housing remain a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
